Retention Agreement between Bristol-Myers Squibb Company & Charles M. Urbain



 Exhibit 10.2 
 PERSONAL & CONFIDENTIAL AGREEMENT 
 Charles M. Urbain 
 300 Main Street 
 Apartment 4C – Meridian Plaza 
 Evansville, Indiana 47708 
 Dear Charles: 
 On behalf of Bristol-Myers Squibb Company (“BMS”), I am pleased to offer you this Letter Agreement. If the BMS Board of Directors decides to proceed with a
sale, spin off, divestiture or other disposition (hereinafter, collectively the “Transformation”) of Mead Johnson Nutritionals (the “Business”), you are being offered the following incentives to ensure that the Business is
managed and operated efficiently throughout the process, the terms and conditions of which are outlined herein: 
  

	1.	Special Performance Bonus Amount. You will be eligible to receive a special cash performance bonus equal to your regular BMS target bonus level (“Special Bonus”) in
effect as of the closing date related to the Transformation of the Business (“Transformation Closing Date”) as follows: 

  

	 	(a)	If your employment transfers to a Successor (i.e., a third party purchaser of the Business or a spin-off of the Business, hereinafter “Successor”) as of the Transformation
Closing Date, you will be paid the Special Bonus as follows: 

  

	 	i.	50% of the Special Bonus will be paid to you within thirty (30) business days following the Transformation Closing Date, and 

  

	 	ii.	The remaining 50% of the Special Bonus will be paid within thirty (30) business days following the six (6) month anniversary of the Transformation Closing Date provided
that you either: (A) remain continuously employed by the Successor, or (B) you are involuntarily terminated other than for cause by the Successor prior to the six (6) month anniversary of the Transformation Closing Date (and in such
case you will be paid the remaining 50% of the Special Bonus within thirty (30) business days of your termination). 

  

	 	(b)	If you remain an employee of BMS after the Transformation Closing Date, you will be paid the Special Bonus as follows: 

  

	 	i.	50% of the Special Bonus will be paid to you within thirty (30) business days following the Transformation Closing Date, and 

  

	 	ii.	You will not be eligible for the remaining 50% of the Special Bonus. 

  

	 	(c)	The Special Bonus will not be paid if for any reason, the Transformation is canceled. Further, if you seek out and transfer to another position at BMS or the Business prior to the
Transformation Closing Date, the Special Bonus will not be paid. The Company retains the right, in its sole discretion, to provide the initial 50% of the Special Bonus to you if you have been asked by the Company to assume other responsibilities
prior to the Transformation Closing Date. 











	2.	Annual Bonus. Provided that you remain an active employee with the Business through the Transformation Closing Date and your employment is transferred to the Successor, you
will be eligible for a pro rata cash bonus at your target bonus level in effect at the time of the Transformation Closing Date, payable in one lump sum for all full or partial months worked during the calendar year in which the date of the transfer
of your employment to the Successor occurs. Other than your right to pro-rata payment under the terms and conditions of this Letter Agreement, the Annual Bonus will be subject to the terms and conditions of the applicable BMS annual bonus plan in
effect as of the transfer date. Such amounts shall be paid within five (5) business days following your “separation from service” from BMS (within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the
“Code”) and final Treas. Reg. §1.409A-1(h)(1)(ii)) (“Separation from Service”). If you remain an employee of BMS after the Transformation Closing Date, you will not be entitled to the pro rata annual bonus contemplated by
this paragraph 2, but you will remain eligible for a bonus under the terms of the applicable BMS bonus plan then in effect. 

  

	3.	Enhanced Severance Payments. You will be eligible for enhanced severance payments if your employment is transferred to the Successor as a result of the Transformation and
your employment is then involuntarily terminated for reasons other than for cause by the Successor prior to the twelve (12) month anniversary date of the Transformation Closing Date. If your employment is terminated under these circumstances,
you will be eligible for the greater of: (i) a total of fifty-two (52) weeks of your base pay in effect as of the date of your termination, or (ii) the severance payments under the applicable BMS severance plan in effect as of the
date of your termination. If there are any severance payments available to you from the Successor, you will receive the difference between those severance payments and the severance payments available to you under this paragraph. Payments under this
Paragraph 3 shall commence immediately after your Separation from Service and shall be payable at regular payroll intervals according to your pay schedule then in effect. The enhanced severance payments described above, if greater than those you
would ordinarily have been entitled to, will be in lieu of, and not in addition to, the severance (if any) that would ordinarily have been payable to you under the terms of the applicable BMS Severance Plan or in any offer letter or other
arrangement between you and BMS. 

  

	4.	Conditions of this Letter Agreement & General Release. The incentive payments and benefits described in this Letter Agreement in paragraphs 1 through 3 above are
contingent upon all of the following conditions: (a) the Transformation Closing Date occurring on or before April 20, 2009; (b) you are an employee in good standing (i.e., meeting the company’s performance expectations) of BMS as
of the Transformation Closing Date; (c) your honoring the need for strict confidentiality regarding the Transformation and the terms of this Letter Agreement, neither of which should be discussed with anyone other than your significant other,
financial or legal advisors without the express and specific permission of a designee of BMS; (d) your providing full support and cooperation in the best interests of BMS and the Business up to and including the Transformation Closing Date; and
(e) throughout the course of your continued employment with BMS and following the completion of the Transformation and/or your separation from BMS, if applicable, your taking no action which would be considered contrary to the best interests of
BMS, the Business, or their affiliates. 

  

 2 








 If you are on an unpaid leave of absence from BMS for more than thirty (30) calendar days at any
time between the date of this Letter Agreement and the Transformation Closing Date, all bonuses as described in paragraphs 1 and 2 will be pro-rated, if permissible under applicable law. A paid approved leave of absence, as specified in the
applicable BMS annual bonus plan in effect as of the Transformation Closing Date, will not impact your eligibility for the bonuses described in paragraphs 1 and 2 above. 
 Finally, in order to receive any of the benefits described in this Letter Agreement, you will be required to sign, timely return, and not revoke, a Separation Agreement which will include a general release of all
claims (in a form satisfactory to BMS), as well as other provisions, including, but not limited to, certain restrictive covenants, which will be provided to you as soon as practicable on or around the Transformation Closing Date. 
  

	5.	Non-Solicitation. As a condition of your receipt of any payments or benefits under this Letter Agreement, commencing on the date of this Letter Agreement and ending on the
date which is one (1) year from the date of your separation from BMS and/or the transfer of your employment to a Successor, (the “Non-Solicitation Period”), you will not, directly or indirectly, solicit for employment, hire, employ or
retain in any capacity, including, but limited to, as an employee, director, independent contractor, consultant or otherwise, other than for employment within BMS or its affiliates, any person who is employed or otherwise engaged on a full or
part-time basis by BMS and/or its affiliates during the Non-Solicitation Period. If you breach this provision, you will pay to BMS the sum of Ten Thousand Dollars ($10,000) for each act of solicitation, not as a penalty, but as liquidated damages
for injuries which precise economic value would be difficult to ascertain. 

 Additionally, you understand and agree that as
part of the Transformation process, BMS and/or the Business may place certain restrictions on certain third-parties prohibiting them from soliciting and or employing employees of the Business and/or BMS and you acknowledge that such restrictions are
permissible. 
  

	6.	Material Breach. Breach the terms of paragraphs 4 or 5 of this Letter Agreement and/or any provisions in the General Release shall constitute a material breach of this Letter
Agreement for which BMS or its affiliates may seek all relief available under the law. 

  

	7.	Not an Employment Agreement. Nothing in this agreement should be construed as a promise of employment for any particular time period. You are and remain an employee at will.


  

	8.	Withholding. It is understood and agreed that all amounts, payments or benefits payable to you as described in this Letter Agreement represent gross amounts and BMS is hereby
authorized to withhold any and all applicable withholdings and taxes from any such amounts, payments or benefits. 

  

	9.	Agreement Applicable in the Context of Change in Control of BMS. In the event of a “change in control” (as such term is defined under the Bristol-Myers Squibb
Company Change In Control Separation Benefits Plan and/or an individual change in control agreement held by you, if applicable), (i) paragraphs 2 and 3 of this Letter Agreement shall automatically be terminated and be null and void as of the
effective date of such “change in control”, and (ii) paragraphs 1, and paragraphs 4 through 15 shall remain in full force and effect. 

  

 3 









	10.	Governing Law; Jurisdiction. This Letter Agreement will be governed by and construed under the laws of the State of New York, without regard to its principles of conflict of
laws. If at any time after the date of this Letter Agreement any provision is held to be illegal, void, or unenforceable, that provision will have no force and effect. However, the illegality or unenforceability of that provision will not have any
effect on, and will not impair the enforceability of, any other provision of this Letter Agreement. If a court of competent jurisdiction finds that the General Release is illegal and/or unenforceable, you will be required to execute a form general
release that is legal and enforceable. 

  

	11.	Amendment/Waiver. No provision in this Letter Agreement may be amended unless agreed to in writing and signed by you and an authorized officer of BMS.


  

	12.	Supersedes All Prior Agreements & Exclusive Retention Benefit. You acknowledge and agree that this Letter Agreement supersedes any and all other prior agreements
entered into between you and BMS with regard to the subject matter hereof, whether written or oral. In the event that any or all other employees of the Business receive or are offered a retention or similar bonus payable upon the Transformation
Closing Date and/or in connection with the Transformation, you understand and agree that you will not be eligible to receive such retention or similar bonuses or benefits, except as explicitly set forth in this Letter Agreement, or as amended
consistent with paragraph 11, above. 

  

	13.	No assignments. You may not assign or delegate any rights or obligations hereunder. BMS may assign this Letter Agreement or delegate any rights hereunder without your consent
to any successor in interest. 

  

	14.	Section 409A. If you are a “specified employee,” as determined by BMS in accordance with the requirements of Code Section 409A(a)(2)(B)(i), then upon your
Separation From Service, payments due to you under this Agreement that are deemed “nonqualified deferred compensation” under Code Section 409A and the final Treasury regulations thereunder (and do not meet any of the exemptions under
Code Section 409A and the final regulations thereunder) shall be delayed until the earlier of (i) six months following the date of your Separation From Service or (ii) the date of the your death. To the fullest extent possible,
amounts and other benefits payable under this Agreement are intended to be exempt from the definition of “nonqualified deferred compensation” under Code Section 409A in accordance with one or more exemptions available under the final
Treasury regulations promulgated under Code Section 409A and, to the extent that any such amount or benefit is or becomes subject to Code Section 409A due to a failure to qualify for an exemption from the definition of “nonqualified
deferred compensation” in accordance with such final Treasury regulations, this Agreement is intended to comply with the applicable requirements of Code Section 409A with respect to such amounts or benefits. This Agreement shall be
interpreted and administered to the extent possible in a manner consistent with the foregoing statement of intent. In no event whatsoever shall BMS or any of its affiliates be liable for any additional tax, interest or penalties that may be imposed
on you or your beneficiary or estate by Code Section 409A or any damages for failing to comply with Code Section 409A. 

  

	15.	Construction & Interpretation. Any determinations by BMS under this Letter Agreement including, but not limited to, determinations regarding eligibility for payments
and benefits hereunder shall be in the sole and absolute discretion of BMS and shall be conclusive and binding on all interested parties. 

  

 4 








 Please acknowledge your understanding of and agreement to the provisions of this Letter Agreement by signing and
returning this letter to me by November 7, 2007. 
  

	
	Very truly yours,
	
	/s/ John Celentano
	 John Celentano
 President, Health Care
Group
 Bristol-Myers Squibb Company

	
	AGREED TO AND ACCEPTED:
	
	/s/ Charles M. Urbain
	Charles M. Urbain

 DATE: 11/7/07 
  

 5 








 AMENDMENT TO LETTER AGREEMENT 
 August 11, 2008 
 Charles M. Urbain 
 300 Main Street 
 Apartment 4C – Meridian Plaza 
 Evansville, Indiana 47708 
 Dear Charles: 
 On behalf of Bristol-Myers Squibb Company (“BMS” or the “Company”), I am pleased to inform you that BMS has approved certain enhancements to the letter agreement between you and BMS, dated
November 7, 2007 (the “Letter Agreement”), which offered you certain incentives to ensure that Mead Johnson (the “Business”) is managed and operated efficiently throughout the process of the Transformation of the Business.
First, this Amendment to the Letter Agreement (“Amendment”) provides clarity that the definitions of Transformation and Successor include an initial public offering or partial public offering of at least ten percent
(10%) (“IPO”) of the Business. Second, the Effective Date of the Letter Agreement has been extended to December 31, 2009. Third, if the BMS Board of Directors determines not to proceed with an IPO of the Business prior to
December 31, 2009, you will remain eligible for the entirety of the Special Bonus and it will no longer be canceled under such circumstances. Fourth, this Amendment explicitly provides that the method of calculating the Special Bonus will be
based on your regular BMS target bonus level and any future bonuses for performance periods post-IPO will be based on the applicable bonus plans of the Business that take effect on or after the IPO. Fifth, the enhanced severance payment has been
extended for involuntary terminations for reasons other than for cause by the Successor to an eighteen (18) month period following the anniversary date of the Transformation Closing Date, which has been increased from a twelve (12) month
period. Furthermore, if your employment is terminated under such circumstances, you will now be eligible for the greater of: (i) a total of eighteen (18) months of your base pay in effect as of the date of such termination, which has been
increased from twelve (12) months of your base pay, or (ii) the severance payments under the applicable BMS severance plan in effect as of the date of such termination. It has also been clarified that, if there are any severance payments
available to you from the Successor, you will receive the greater of those severance payments or the severance payments available to you under the paragraph relating to the enhanced severance payment, but not both. Finally, if an IPO of the Business
occurs prior to December 31, 2009, and you are an employee of the Business after the Transformation Closing Date, you will also remain eligible for benefits under the Bristol-Myers Squibb Change In Control Separation Benefits Plan (“BMS
CIC Plan”), provided benefits under the BMS CIC Plan are available to similarly situated employees at your grade level or its equivalency at Bristol-Myers Squibb Company. 
 Capitalized terms not otherwise defined or modified herein have the meanings ascribed to them in the Letter Agreement. 









 The definitions of “Transformation” and “Successor” in the Letter Agreement are hereby amended to
include an IPO of the Business. 
 Paragraph 1(c) of the Letter Agreement is hereby amended in its entirety to read as follows: 
  

	 	 (c)
	 (i) The Special Bonus will be paid if (A) the IPO is canceled by BMS prior to December 31, 2009, and
(B) you are an active employee and in good standing of the Business as of the date the decision to cancel the IPO is made. The Special Bonus will be paid approximately six (6) months following the date the decision is made to cancel the
IPO, but in no event later than March 15th of the calendar year following the date the decision to cancel the IPO is made, to comply with
Internal Revenue Code Section 409A. 


 (ii) The Special Bonus will not be paid in the event (A) you seek out
and transfer to another position at BMS or the Business prior to the Transformation Closing Date, (B) the Transformation takes a form other than the IPO and is then canceled prior to December 31, 2009; or (C) except as otherwise
provided in paragraph 1(c)(i) above, the Transformation Closing Date does not occur on or before December 31, 2009. 
 (iii) The
Company retains the right, in its sole discretion, to provide the initial 50% of the Special Bonus to you if you have been asked by the Company to assume other responsibilities prior to the Transformation Closing Date in the time period described in
paragraph 1(a)i. above. 
 Paragraph 1(d) is hereby added to the Letter Agreement so as to immediately follow Paragraph 1(c) as follows: 
  

	 	(d)	In the event you are eligible for a Special Bonus under sub-section 1(a), 1(b) or 1(c)(iii), the calculation of the Special Bonus will be based on your regular BMS target bonus
level in effect immediately prior to the Transformation Closing Date. In the event you are eligible for a Special Bonus under sub-section 1(c)(i), the calculation of the Special Bonus will be based on your regular BMS target bonus level in effect
immediately prior to the date the decision to cancel the IPO is made. In the event of an IPO, your target cash bonus for performance periods post-IPO will be based on the applicable bonus plans and programs in effect for Business employees and such
plans and programs will have no relevance to the calculation of the Special Bonus. 

 Paragraph 3 of the Letter Agreement is hereby amended in
its entirety to read as follows: 
  

	3.	 Enhanced Severance Payments. You will be eligible for enhanced severance payments if your employment is transferred to the Successor as a result of the
Transformation and your employment is then involuntarily terminated for reasons other than for cause by the Successor prior to the eighteen (18) month anniversary 



  

 2 









	 	 
date of the Transformation Closing Date. If your employment is terminated under these circumstances, you will be eligible for the greater of: (i) a
total of eighteen (18) months of your base pay in effect as of the date of your termination by the Successor, or (ii) the severance payments under the applicable BMS severance plan in effect as of the date of your termination by the
Successor. If there are any severance payments available to you from the Successor, you will receive the greater of those severance payments or the severance payments available to you under this paragraph, but not both. Payments under this Paragraph
3 shall commence immediately after your Separation from Service by the Successor and shall be payable at regular payroll intervals according to your pay schedule then in effect. The enhanced severance payments described above, if greater than those
you would ordinarily have been entitled to, will be in lieu of, and not in addition to, the severance (if any) that would ordinarily have been payable to you under the terms of the applicable BMS Severance Plan or in any offer letter or other
arrangement between you and BMS. 


 Paragraph 4 of the Letter Agreement is hereby amended in its entirety to read as follows: 

 

	4.	Conditions of this Letter Agreement & General Release. The incentive payments and benefits described in this Letter Agreement in Paragraphs 1 through 3 above are
contingent upon all of the following conditions: (a) the Transformation Closing Date occurring on or before December 31, 2009, except as otherwise provided in paragraph 1(c)(i) above; (b) you are an employee in good standing (i.e.,
meeting the company’s performance expectations) of BMS as of the Transformation Closing Date; (c) your honoring the need for strict confidentiality regarding the Transformation; (d) your honoring the need for strict confidentiality
regarding the terms of this Letter Agreement, which should not be discussed with anyone other than your significant other, financial or legal advisors without the express and specific permission of a designee of BMS; (e) your providing full
support and cooperation in the best interests of BMS and the Business up to and including the Transformation Closing Date; and (f) throughout the course of your continued employment with BMS and following the completion of the Transformation
and/or your separation from BMS, if applicable, your taking no action which would be considered contrary to the best interests of BMS, the Business, or their affiliates. 

 If you are on an unpaid leave of absence from BMS for more than thirty (30) calendar days at any time between the date of this Letter Agreement and
the Transformation Closing Date, all bonuses as described in Paragraphs 1 and 2 will be pro-rated, if permissible under applicable law. A paid approved leave of absence, as specified in the applicable BMS annual bonus plan in effect as of the
Transformation Closing Date, will not impact your eligibility for the bonuses described in Paragraphs 1 and 2 above. 
 Finally, in order
to receive any of the benefits described in this Letter Agreement, you will be required to sign, timely return, and not revoke, a Separation Agreement which will include a general release of all claims (in a form satisfactory to BMS), as well as
other provisions, including, but not limited to, certain restrictive covenants, which will be provided to you as soon as practicable on or around the Transformation Closing Date. 
  

 3 








 Paragraph 9 of the Letter Agreement is hereby amended in its entirety to read as follows: 
  

	9.	Agreement Applicable in the Context of Change in Control of BMS. In the event of a “change in control” (as such term is defined under the Bristol-Myers Squibb
Company Change In Control Separation Benefits Plan (“BMS CIC Plan”) prior to the Transformation Closing Date, this Letter Agreement shall automatically be terminated and be null and void as of the effective date of such “change in
control.” If the Transformation (i) is an IPO of the Business, (ii) the Business becomes and/or remains a subsidiary of BMS, and (iii) you remain an employee either of BMS or of the Business after the Transformation Closing Date,
you will remain eligible for benefits under the BMS CIC Plan if a change in control of BMS occurs, provided that benefits under the BMS CIC Plan are available to similarly situated employees in your grade level or its equivalency at BMS. In no case,
however, will you be eligible for benefits under the BMS CIC Plan if a change in control of the Business occurs. 

 All other provisions of the
Letter Agreement remain unchanged and in full force and effect. 
 Pursuant to Paragraph 11 of the Letter Agreement, no provision of the Letter Agreement may
be amended unless such amendment is agreed to in writing and signed by you and an authorized officer of BMS. Accordingly, in order for the enhancements to the Letter Agreement set out in the Amendment to have effect, you must acknowledge your
understanding of and agreement to the terms of the Amendment by signing and returning this letter to me no later than August 25, 2008. 
  

	
	Very truly yours,
	
	/s/ Stephen W. Golsby
	 Stephen W. Golsby
 President, Mead Johnson
Nutritionals

	
	AGREED TO AND ACCEPTED:
	
	/s/ Charles M. Urbain
	Charles M. Urbain

  

 4